---
title: "Asahi Kasei to Acquire Veloxis Pharmaceuticals for $1.3 Billion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/273676767.md"
datetime: "2026-01-26T09:09:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273676767.md)
  - [en](https://longbridge.com/en/news/273676767.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273676767.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/273676767.md) | [繁體中文](https://longbridge.com/zh-HK/news/273676767.md)


# Asahi Kasei to Acquire Veloxis Pharmaceuticals for $1.3 Billion

Asahi Kasei is set to acquire Veloxis Pharmaceuticals Inc., a U.S.-based pharmaceutical company, through its Danish subsidiary. The transaction involves a voluntary tender offer for all ordinary shares and warrants of Veloxis Pharmaceuticals A/S, which owns 100% of Veloxis. The deal, valued at approximately USD 1.3 billion, is intended to accelerate Asahi Kasei’s transformation into a global health care company by strengthening its pharmaceutical presence in the U.S. market and creating synergies between its existing operations in Japan and Asia and Veloxis’ business platform in the United States. The acquisition aims to boost licensing activities, expand the pipeline of new pharmaceuticals, and enhance access to innovation and clinical practices in the U.S. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Asahi Kasei Corporation published the original content used to generate this news brief on January 26, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [Asahi Kasei Corporation (3407.JP)](https://longbridge.com/en/quote/3407.JP.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [Vertex Pharmaceuticals Incorporated (VRTX.US)](https://longbridge.com/en/quote/VRTX.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [Asahi Kasei Corporation (AHKSY.US)](https://longbridge.com/en/quote/AHKSY.US.md)

## Related News & Research

- [Glenmark Pharma to directly commercialize and distribute Ryaltris in U.S. effective](https://longbridge.com/en/news/281370208.md)
- [Vertex Pharmaceuticals Says US FDA Approves Label Expansion for Alyftrek, Trikafta](https://longbridge.com/en/news/281365753.md)
- [Vertex Pharmaceuticals Inc - FDA expands indication for trikafta in cf patients ages 2 and older](https://longbridge.com/en/news/281371049.md)
- [Elite Pharmaceuticals launches generic methadone tablets; 2025 category sales ~$22M](https://longbridge.com/en/news/281522306.md)
- [EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025](https://longbridge.com/en/news/281015927.md)